AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02615912 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5%
Study NCT02615912 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5%
Study NCT02615912 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Silwet* DA-63 (Momentive) 1.5%
Study NCT02615912 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sodium lauryl sulfate (Sigma Aldrich) 1.0%
Study NCT02615912 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Water (control)
Study NCT04286165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief Peer Supported webSTAIR
Description: The BPS webSTAIR program is an online platform where individuals are taught skills in emotion regulation. In this program they will learn how to recognize the emotions they are feeling by assessing their own body language, being attentive to their thought processes, and attempting to replace negative behaviors with positive. Throughout the platform they will engage in written exercises to help them solidify the lessons with their own life experiencing. They will also have the support of peers throughout the program to help them when they need clarification or having a difficult time applying the lesson(s).
Study NCT02159963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised training
Description: 8 weeks high intensity interval training, 3 times a week, one is supervised, two are home based unsupervised.
Study NCT02159963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unsupervised training
Description: 8 weeks home based high-intensity-interval cycle-training 3 times a week.
Study NCT02159963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optional training
Description: 8 weeks of optional home based, unsupervised training.
Study NCT02159963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: 8 weeks of control period. Participants are doing daily living.
Study NCT00587418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: Arginaid (Novartis) 1 package (9.2g) bid for 7 days
Study NCT00587418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder 9.2g bid for 7 days
Study NCT04097626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition education
Description: The experimental group will receive nutrition education once during the study. It will occur at the beginning of the second week. This will consist of a 30-minute interactive lecture and a 15-minute question-and-answer session. The information covered will be basic nutrition principles for good health and to support regular exercise.
Study NCT04097626 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no nutrition education
Description: This group will not receive nutrition education.
Study NCT02272400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IGRT for prone partial breast irradiation (PBI)
Description: IGRT for prone partial breast irradiation (PBI): All patients will be treated prone with 6 Gy/fraction delivered in 5 fractions over a 1-week period for a total dose of 30 Gy. Simulation and treatment will be started within 50 days from surgery in order to maximize the chances of optimal lumpectomy cavity visualization on the planning and cone beam CT scans. All patients will be followed monthly for the first 90 days then q3 months for the first year, then yearly for the next 10 years.
Study NCT03037749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Description: Alcohol beverage measured to have participant achieve a BAC of 0.08%
Study NCT03037749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo beverage
Description: Placebo beverage measured to mimic the smell and taste of the alcohol beverage.
Study NCT03495414 — intervention group
Intervention type: OTHER
Intervention: Brain Imaging
Description: * Structural MRI (T1 weighted)~* Diffusion Tensor Imaging (DTI)~* resting state functional MRI (rs-fMRI)~* functional MRI (fMRI): Brain activity will be measured in response to sexual images (visually evoked sexual arousal; processing of sexual stimuli), and importantly during a phase when these stimuli are anticipated (neural correlates of wanting and desire; reward anticipation).
Study NCT01730040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe over-encapsulated tablet orally.
Study NCT03495414 — intervention group
Intervention type: OTHER
Intervention: Cognitive testing
Description: We will administer neuropsychological tests assessing objective measures for~* intelligence (Ravens Matrices)~* impulsivity and risk-taking behavior (Balloon Analogue Risk Task)~* inhibitory control (Stop Signal Task).
Study NCT03495414 — intervention group
Intervention type: OTHER
Intervention: Psychometric
Description: Administered questionnaires include anxiety and depression symptoms (MADRS, HADS, GAD), drug use (AUDIT, DUDIT), attention deficits (ASRS), impulsivity (BIS-11), reward seeking behavior (BIS/BAS), sexual orientation, (hyper)sexual behavior, desire and compulsivity aspects (HDSI, HBI, SCS, SDI, SIS/SES).
Study NCT01730040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin over-encapsulated tablets orally.
Study NCT01730040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for alirocumab and ezetimibe.
Study NCT01730040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for alirocumab and ezetimibe.
Study NCT03495414 — intervention group
Intervention type: OTHER
Intervention: Blood test
Description: Blood samples will be taken for routine health assessment, measurement of sex hormonal levels, HPA-axis function test (dexamethasone suppression), and potential DNA extraction and (epi)genetic profiling.
Study NCT01043471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum
Description: Subjects were instructed to chew gum at least 6 times a day in an effort to reduce snacking.
Study NCT01043471 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Subjects were instructed to drink 8 oz of water at least 6 times a day in an effort to reduce snacking.
Study NCT03947957 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: collection of expectoration, stools and blood
Description: collection of expectoration, stools and blood
Study NCT01628315 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: Annual MRIs as part of participation in the ASA study.
Study NCT04325646 — intervention group
Intervention type: OTHER
Intervention: Human Biological samples
Description: Blood samples for serological tests
Study NCT02583945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: kidney treatment bundle (KDIGO)
Description: Application of the measures of the kidney treatment bundle.
Study NCT00409604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporary RV VVI pacing
Description: temporary pacing at the onset of revascularisation
Study NCT03417180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: a rate of infusion of reminfentanil will be increased by 50% every 5 minutes, until SPI value decreases back to baseline level
Study NCT03417180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: surgical pleth index
Description: every time SPI value increases by 15 a rate of infusion of reminfentanil will be increased by 50% every 5 minutes
Study NCT02586636 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Metformin is given alongside omeprazole / placebo. Started at low dose and titrated gradually over four weeks according to the individual's tolerance of metformin. We anticipate that their tolerance of metformin will be reduced by loss of function variants in OCT1, and by concurrent use of OCT1 inhibiting drugs (in our study this is omeprazole).
Study NCT02586636 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole
Description: Given as concurrent treatment in one of the two treatment periods. Omeprazole treatment dose is fixed at 20mg twice daily for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
Study NCT02586636 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Given as concurrent treatment in one of the two treatment periods. Placebo treatment dose is fixed at one tablet twice daily (to match the dosing pattern of omeprazole) for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
Study NCT03381599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim Injection
Description: Filgrastim of 10 ug/kg/day will be given for four serial days.
Study NCT04111458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1701963
Description: Tablet
Study NCT04296500 — intervention group
Intervention type: OTHER
Intervention: Decision tree modeling
Description: A decision tree analysis was employed to explore the process of decision-making on types of pattern based on the existence or nonexistence of a symptom. At the end of tree presented is the proportion of patients who are categorised into each pattern.~In this study, the classification was performed by applying the classification and regression tree (CART) algorithm using Scikit-learn package of Python, which performs a division using the Gini coefficient or the decrement of dispersion. The Gini coefficient is one of the tools for measuring entropy or diversity in each node and it measures the decrement by comparing the information entropy before and after separation. To avoid overfitting, the maximum number of leaf nodes was limited to four and the pruning method which complied with the principle of minimum description length was applied.
Study NCT02028546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bathing and moisturizer application
Description: regimen 1: soaking an arm for 10 minutes, no moisturizer application regimen 2: soaking an arm for 10 minutes,immediate moisturizer application regimen 3: soaking an arm for 10 minutes, delayed moisturizer application for 30 min.~regimen 4: wait for 10 minutes,no soaking, moisturizer application (moisturizer alone) (All regimens were completed in all patients with 2 visits (7 days interval))
Study NCT02396823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training
Description: Standard threshold Positive Expiratory Pressure Device and threshold Inspiratory Muscle Trainer assembled together using a T-shaped connector with flanged mouthpiece will be used. The participants will be instructed to perform inspiratory and expiratory efforts against a resistive load. Training session lasts 45 minutes per day, 5 days per week, for 4 weeks.
Study NCT00972244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: once daily, 12 weeks
Study NCT00972244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, 12 weeks
Study NCT01649739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra
Description: There is 2 dosage:10mg Twice daily and 20mg Twice daily
Study NCT04141787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice.
Study NCT04141787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)
Description: Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice.
Study NCT00862966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: citrate
Description: comparison of different catheter lock solutions
Study NCT00862966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: heparin
Description: comparison of different lock solutions
Study NCT02884817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: essential oils and ELA
Description: The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the Experimental solution, Listerine Gum Therapy. This oral hygiene routine was repeated for 21d.
Study NCT02884817 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the 21.6% hydroalcoholic solution. This oral hygiene routine was repeated for 21d.
Study NCT02884817 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water
Description: The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the sterile water, sham comparator. This oral hygiene routine was repeated for 21d.
Study NCT04111458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Tablet
Study NCT00953628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10000 IU urinary HCG
Description: bolus 10000 units for ovulation triggering
Study NCT00953628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mcg recombinant HCG
Description: bolus 250 mcg for ovulation triggering in IVF patients
Study NCT02610439 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03667820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib 80mg tablet to be taken once daily.
Study NCT03667820 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: Stereotactic Ablative Radiation (SABR)
Study NCT04493476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chinese herbal formula
Description: Chinese herbal formula
Study NCT04493476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chinese herbal formula
Description: Chinese herbal formula
Study NCT00194792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given PO
Study NCT00194792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin pamoate
Description: Given IM
Study NCT00194792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO
Study NCT00194792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT00194792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV
Study NCT00194792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00194792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo lumpectomy or mastectomy
Study NCT00194792 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT00194792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00255151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
Study NCT00255151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
Study NCT00255151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
Study NCT02820740 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NeuroBlate System
Description: Laser Interstitial Thermal Therapy
Study NCT03547635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AMNIOEXCEL Plus Amniotic Membrane
Description: AMNIOEXCEL Plus is a human placental-based tissue consisting of dehydrated, tri-layer Placental (Amnion/Chorion/Amnion) Allograft Membrane (T-PAM) layers. T-PAM is a minimally manipulated placental membrane product made from tissues donated by pre-screened mothers during planned C-sections and is intended for use as a wound covering. This product is an allograft tissue intended for homologous use for the repair, reconstruction and replacement of skin at the direction of a physician. AMNIOEXCEL Plus contains Human Cellular and Tissue Based Products (HCT/P) as defined by US FDA 21 CFR Part 1271. All donor recoveries are performed by BioDlogics, LLC, and adhere to the regulations regarding HCT/P recovery and the screening and testing of the tissue donor as verified through supplier audits.
Study NCT03547635 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A Marketed Comparator
Description: bi-layered skin substitute: the epidermal layer is formed by human keratinocytes and has a well-differentiated stratum corneum; the dermal layer is composed of human fibroblasts in a bovine Type I collagen lattice. It is indicated for use with standard therapeutic compression for the treatment of non-infected partial and full-thickness skin ulcers due to venous insufficiency of greater than 1-month duration and which have not adequately responded to conventional ulcer therapy. This product is also indicated for use with standard DFU care for the treatment of full-thickness neuropathic DFUs of greater than three weeks' duration which have not adequately responded to conventional ulcer therapy and which extend through the dermis but without tendon, muscle, capsule or bone exposure.
Study NCT03547635 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: * Coban™~* Conforming gauze~* Optifoam® non-adhesive dressing~* Cotton Gauze~* Normal saline (liquid or gel)~* Non-adhering dressings~* Steristrips~* An offloading boot (Pneumatic Short Leg Walker), as appropriate
Study NCT02073006 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Natural Fibre Supplement
Description: Natural Fibre Supplement 2 doses per day for 4 weeks
Study NCT02073006 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Natural Fibre Supplement
Description: Natural Fibre Supplement 2 doses per day for 4 weeks
Study NCT02697539 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AmF/SnF2
Description: AmF/SnF2 dentifrice used twice daily for 2 minutes for 12 weeks
Study NCT02947568 — intervention group
Intervention type: OTHER
Intervention: non-interventional study
Study NCT05416671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: guided narrative technique-writing
Description: The experimental group underwent the psychological intervention of guided narrative technique-writing with the theme of teacher criticism for 20 to 30 minutes once a day for three consecutive days.
Study NCT03276936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX103 1.5%
Description: FMX103 1.5% minocycline foam